Evidence map›Paper›PMID 33844185›Full record

ArticleAnnals of nuclear medicine2021

In vivo detection of beta-amyloid at the nasal cavity and other skull-base sites: a retrospective evaluation of ADNI1/GO.

Anish Kapadia, Prarthana Desai, Adam Dmytriw, Pejman Maralani, Chris Heyn, Sandra Black, Sean Symons, Alzheimer’s Disease Neuroimaging Initiative

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. [1-Fluids and barriers of the CNS · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Anish KapadiaDepartment of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, M4N 3M5, Canada. anish.kapadia@mail.utoronto.ca.ORCID http://orcid.org/0000-0002-8779-1962
Prarthana DesaiDepartment of Medicine, Maharaja Sayajirao University of Baroda, Vadodra, 390002, India.
Adam DmytriwDepartment of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, M4N 3M5, Canada.
Pejman MaralaniDepartment of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, M4N 3M5, Canada.
Chris HeynDepartment of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, M4N 3M5, Canada.
Sandra BlackHurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.
Sean SymonsDepartment of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, M4N 3M5, Canada.
Alzheimer’s Disease Neuroimaging Initiative
Sunnybrook Health Science Centre · CAMaharaja Sayajirao University of Baroda · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAmyloid beta (Aβ) is partially cleared from the CSF via skull base perivascular and perineural lymphatic pathways, particularly at the nasal cavity. In vivo differences in Aβ level at the nasal cavity between patients with Alzheimer's disease (AD), subjects with mild cognitive impairment (MCI) and cognitively normal (CN) individuals have not been previously assessed.

methodsThis is a retrospective evaluation of subject level data from the ADNI-1/GO database. Standardized uptake value ratio (SUVR) maximum on

results103 subjects with 223 PiB-PET scans (47 CN, 32 AD and 144 MCI) were included in the study. The SUVR maxima at the nasal cavity were significantly lower in subjects with AD [1.35 (± 0.31)] compared to CN [1.54 (± 0.30); p = 0.024] and MCI [1.49 (± 0.33); p = 0.049]. At very low CSF Aβ, less than 132 pg/ml, there was significant correlation with nasal cavity SUVR maximum. The summed averaged SUVR maximum values were significantly lower in subjects with AD [1.35 (± 0.16)] compared to CN [1.49 (± 0.17); p = 0.003] and MCI [1.40 (± 0.17); p = 0.017].

conclusionPatients with AD demonstrate reduced nasal cavity PiB-PET radiotracer uptake compared to MCI and CN, possibly representing reduced Aβ clearance via perineural/perivascular lymphatic pathway. Further work is necessary to elucidate the true nature of this finding.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesNasal CavityPositron-Emission TomographySkull BaseAgedAged, 80 and overAniline CompoundsCognitive DysfunctionFemaleHumansMaleMiddle AgedRetrospective StudiesThiazoles2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAmyloid beta-PeptidesAniline CompoundsThiazolesAlzheimer’s AmyloidNeurologyPathogenesis

Identifiers

PMID33844185
OpenAlexW3153113600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.